SEARCH

SEARCH BY CITATION

References

  • 1
    Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975; 256: 495497.
  • 2
    Ross JS, Schenkein DP, Pietrusko R, Rolfe M, Linette GP, Stec J, Stagliano NE, Ginsburg GS, Symmans WF, Pusztai L, Hortobagyi GN. Targeted therapies for cancer. Am J Clin Pathol 2004; 122: 598609.
  • 3
    McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME, Heyman MR, Bence-Bruckler I, White CA, Cabanillas F, Jain V, Ho AD, Lister J, Wey K, Shen D, Dallaire BK. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of the patients respond to a four-dose treatment program. J Clin Oncol 1998; 16: 28252833.
  • 4
    Pulte D, Gondos A, Brenner H. On-going improvement in outcomes for patients diagnosed as having non-Hodgkin's lymphoma from 1990s to the 21st century. Arch Intern Med 2008; 168: 469476.
  • 5
    Dimitrov DS, Marks JD. Therapeutic antibodies: current state and future trends – is a paradigm change coming soon? In: Therapeutic Antibodies: Methods and Protocols, Vol. 525, ed. Dimitrov AS . Berlin: Humana Press, Springer, 2009; 127.
  • 6
    Weiner LM, Dhodapkar MV, Ferrone S. Monoclonal antibodies for cancer immunotherapy. Lancet 2009; 373: 10331040.
  • 7
    Glennie MJ, van de Winkel JGJ. Renaissance of cancer therapeutic antibodies. Drug Discov Today 2003; 8: 503510.
  • 8
    Chari RVJ. Targeted delivery of chemotherapeutics: tumor-activated prodrug therapy. Adv Drug Deliv Rev 1998; 31: 89105.
  • 9
    Lambert JM. Drug-conjugated monoclonal antibodies for the treatment of cancer. Curr Opin Pharmacol 2005; 5: 543549.
  • 10
    Blättler WA, Chari RVJ. Drugs to enhance the therapeutic potency of anticancer antibodies: antibody-drug conjugates as tumor-activated prodrugs; Chapter 19. In: Anticancer Agents: Frontiers in Cancer Chemotherapy, Vol. 796, eds Ojima I , Vite GD , Altmann K-H . Washington, DC: ACS Symposium Series, 2001; 317338.
  • 11
    Lambert JM. Antibody-maytansinoid conjugates: a new strategy for the treatment of cancer. Drugs Future 2010; 35: 471480.
  • 12
    Vater CA, Goldmacher VS. Antibody-cytotoxic compound conjugates for oncology. In: Macromolecular Anticancer Therapeutics, Cancer Drug Discovery and Development 2010, Part 4, eds Reddy LH , Couvreur P . Berlin: Springer, 2010; 331369.
  • 13
    Carter PJ, Senter PD. Antibody-drug conjugates for cancer therapy. Cancer J 2008; 14: 154169.
  • 14
    Smith AL, Nicolaou KC. The enediyne antibiotics. J Med Chem 1996; 39: 21032117.
  • 15
    Ricart AD. Antibody drug conjugates of calicheamicin derivative: gemtuzumab ozogamicin and inotuzumab ozogamicin. Clin Cancer Res 2011; 17: 64176427.
  • 16
    Bross PF, Beitz J, Chen G, Chen XH, Duffy E, Kieffer L, Roy S, Sridhara R, Rahman A, Williams G, Pazdur R. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res 2001; 7: 14901496.
  • 17
    Sievers EL, Larson RA, Stadtmauer EA, Estey E, Lowenberg B, Dombret H, Karanes C, Theobald M, Bennett JM, Sherman ML, Berger MS, Eten CB, Loken MR, van Dongen JJ, Bernstein ID, Appelbaum FR. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol 2001; 19: 32443254.
  • 18
    Petersdorf S, Kopecky K, Stuart RK, Larson RA, Nevill TJ, Stenke L, Slovak ML, Tallman MS, Willman CL, Erba H, Appelbaum FR. Preliminary results of Southwest Oncology Group Study SO106: an international intergroup phase 3 randomized trial comparing the addition of gemtuzumab ozogamicin to standard induction therapy versus standard induction therapy followed by a second randomized to post-consolidation gemtuzumab ozogamicin versus no additional therapy for previously untreated acute myeloid leukemia. Blood 2009; 114: 326. abstr 790.
  • 19
    Ravandi F. Gemtuzumab ozogamicin: one size does not fit all – the case for personalized therapy. J Clin Oncol 2011; 29: 349351.
  • 20
    Burnett AK, Hills RK, Milligan D, Kjeldsen L, Kell J, Russell NH, Yin JAL, Hunter A, Goldstone AH, Wheatley K. Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. J Clin Oncol 2011; 29: 369377.
  • 21
    Castaigne S, Pautas C, Terre C, Raffoux E, Bordessoule D, Bastie J-N, Legrand O, Thomas X, Turlure P, Reman O, de Revel T, Gastaud L, de Gunzburg N, Contentin N, Henry E, Marolleau J-P, Aljijakli NA, Rousselot P, Fenaux P, Preudhomme C, Chevret S, Dombret H. Effect of gemtuzumab ozogamicin on survival of adult patients with de novo acute myeloid leukemia (ALFA-0701): a randomized, open-label, phase 3 study. Lancet 2012; 379: 15081516.
  • 22
    Advani A, Coiffier B, Czuczman MS, Dreyling M, Foran J, Gine E, Gisselbrecht C, Ketterer N, Nasta S, Rohatiner A, Schmidt-Wolf IGH, Schuler M, Sierra J, Smith MR, Verhoef G, Winter JN, Boni J, Vandenries E, Shapiro M, Fayad L. Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-Cell non-Hodgkin's lymphoma: results of a phase I study. J Clin Oncol 2010; 28: 20852093.
  • 23
    Giles FJ, Kantarjian HM, Kornblau SM, Thomas DA, Garcia-Moreno G, Waddelow TA, David CL, Phan AT, Colburn DE, Rashid A, Estey EH. Mylotarg [gemtuzumab ozogamicin] therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation. Cancer 2001; 92: 406413.
  • 24
    Wadleigh M, Richardson PG, Zahrieh D, Lee SJ, Cutler C, Ho V, Alyea EP, Antin JH, Stone RM, Soiffer RJ, DeAngelo DJ. Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation. Blood 2003; 102: 15781582.
  • 25
    Kantarjian H, Thomas D, Jorgensen J, Jabbour E, Kebriaei P, Rytting M, York S, Ravavdi F, Kwari M, Faderl S, Rios MB, Cortes J, Fayad L, Tarnai R, Wang SA, Champlin R, Advani A, O'Brien S. Inotuzumab ozogamicin, an anti-CD22-calicheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study. Lancet Oncol 2012; 13: 403411.
  • 26
    Terrett JA, Gangwar S, Rao-Naik C, Pan C, Guerlavais V, Huber M, Chong C, Green L, Cardarelli P, King D, Deshpande S, Rangan V, Coccia M, Lu L, Passmore D, Blansett D, Dai R, Sufi B, Zhang Q, Chen L, Soderberg C, Kwok E, Horgan K, Cortez O, Sattari P. Single, low dose treatment of lymphoma and renal cancer xenografts with human anti-CD70 antibody-toxin conjugates, results in long term cures. Proc Am Assoc Cancer Res 2007; 48: abstr 4112.
  • 27
    Sapra P, Stein R, Pickett J, Qu Z, Govindan SV, Cardillo TM, Hansen HJ, Horak ID, Griffiths GL, Goldenberg DM. Anti-CD74 antibody-doxorubicin conjugate IMMU-110, in a human multiple myeloma xenograft and in monkeys. Clin Cancer Res 2005; 11: 52575264.
  • 28
    Dumontet C, Jordan MA. Microtubule-binding agents: a dynamic field of cancer therapeutics. Nat Rev Drug Discov 2010; 9: 790803.
  • 29
    Lyon RP, Meyer DL, Setter JR, Senter PD. Conjugation of anticancer drugs through endogenous monoclonal antibody cysteine residues. Methods Enzymol 2012; 502: 123138.
  • 30
    Senter PD, Sievers EL. The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Nat Biotechnol 2012; 30: 631637.
  • 31
    Goldmacher VS, Chittenden T, Chari RVJ, Kovtun YV, Lambert JM. Antibody-drug conjugates for targeted cancer therapy. Annu Rep Med Chem 2012; 47: 349366.
  • 32
    Wang L, Amphlett G, Blättler WA, Lambert JM, Zhang W. Structural characterization of the maytansinoid-monoclonal antibody immunoconjugate, huN901-DM1, by mass spectrometry. Protein Sci 2005; 14: 24362446.
  • 33
    Erickson HK, Lambert JM. ADME of antibody-maytansinoid conjugates. AAPS J 2012; 14: 799805.
  • 34
    Erickson HK, Lewis Phillips GD, Leipold DD, Provenzano CA, Mai E, Johnson HA, Gunter B, Audette CA, Gupta M, Pinkas J, Tibbitts J. The effect of different linkers on target cell catabolism and pharmacokinetics/pharmacodynamics of trastuzumab maytansinoid conjugates. Mol Cancer Ther 2012; 11: 11331142.
  • 35
    Kellogg BA, Garrett L, Kovtun Y, Lai KC, Leece B, Miller M, Payne G, Steeves R, Whiteman KR, Widdison W, Xie H, Singh R, Chari RVJ, Lambert JM, Lutz RJ. Disulfide-linked antibody-maytansinoid conjugates: optimization of in vivo activity by varying the steric hindrance at carbon atoms adjacent to the disulfide linkage. Bioconjug Chem 2011; 21: 8492.
  • 36
    Francisco JA, Cerveny CG, Meyer DL, Mixan BJ, Klussman K, Chace DF, Rejniak SX, Gordon KA, DeBlanc R, Toki BE, Law C-L, Doronina SO, Siegall CB, Senter PD, Wahl AF. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood 2003; 102: 14581465.
  • 37
    Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, Ramchandren R, Bartlett NL, Cheson BD, de Vos S, Forero-Torres A, Moskowitz CH, Connors JM, Engert A, Larsen EK, Kennedy DA, Sievers EL, Chen R. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodkgin's lymphoma. J Clin Oncol 2012; 30: 21832189.
  • 38
    Pro B, Advani R, Brice P, Bartlett NL, Rosenblatt JD, Illidge T, Matous J, Ramchandren R, Fanale M, Connors JM, Yang Y, Sievers EL, Kennedy DA, Shustov A. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic lage-cell lymphoma: results of a phase II trial. J Clin Oncol 2012; 30: 21902196.
  • 39
    Younes A, Bartlett NL, Leonard JP, Kennedy DA, Lynch CM, Sievers EL, Forero-Torres A. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 2010; 363: 18121821.
  • 40
    Fanale MA, Forero-Torres A, Rosenblatt JD, Advani RH, Franklin AR, Kennedy DA, Han TH, Sievers EL, Bartlett NL. A phase I weekly dosing study of brentuximab vedotin in patients with relapsed/refractory CD30-positive hematologic malignancies. Clin Cancer Res 2012; 18: 248255.
  • 41
    Advani R, Oki Y, Shustov A, Grove LE, Bartlett NL. Brentuximan vedotin for relapsed or refractory non-Hodgkin lymphoma: preliminary results from a phase 2 study. J Clin Oncol 2012; 30: (Suppl.): abstr 8070.
  • 42
    Lewis Phillips GD, Li G, Dugger D, Crocker LM, Parsons KL, Mai E, Blättler WA, Lambert JM, Chari RJ, Lutz RJ, Wong WLT, Jacobson FS, Koeppen H, Schwall RH, Kenkare-Mitra SR, Spenser SD, Sliwkowski MX. Targeting HER2-positive breast cancer with trastuzumab-DM1, and antibody–cytotoxic drug conjugate. Cancer Res 2008; 68: 92809290.
  • 43
    Erickson HK, Widdison WC, Mayo MF, Whiteman K, Audette C, Wilhelm SD, Singh R. Tumor delivery and in vivo processing of disulfide-linked and thioether-linked antibody-maytansinoid conjugates. Bioconjug Chem 2010; 21: 8492.
  • 44
    Shen B-Q, Bumbaca D, Saad O, Yue Q, Pastuskoas CV, Khojasteh SC, Tibbits J, Kaur S, Wang B, Chu Y-W, LoRusso PM, Girish S. Catabolic fate and pharmacokinetic characterization of trastuzumab emtansine: an emphasis on preclinical and clinical catabolism. Curr Drug Metab 2012; 13: 901910.
  • 45
    Krop IE, Beeram M, Modi S, Jones SF, Holden SN, Yu W, Girish S, Tibbetts J, Yi J-H, Sliwkowski MX, Jacobson F, Lutzker SG, Burris HA. Phase I study of trasuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. J Clin Oncol 2010; 28: 26982704.
  • 46
    Beeram M, Krop IE, Burris HA, Girish S, Yu W, Lu MW, Holden SN, Modi S. A phase 1 study of weekly dosing of trastuzumab emtansine (T-DM1) in patients with advanced human epidermal growth factor 2-positive breast cancer. Cancer 2012; 118: 57335740.
  • 47
    Burris HA III, Rugo HS, Vukelja SJ, Vogel CL, Borson RA, Limentani S, Tan-Chiu E, Krop IE, Michaelson RA, Girish S, Amler L, Zheng M, Chu Y-W, Klencke B, O'Shaughnessy JA. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J Clin Oncol 2011; 29: 398405.
  • 48
    Krop I, LoRusso P, Miller KD, Modi S, Yardley D, Rodriguez G, Lu M, Burington B, Agresta S, Rugo H. A phase 2 study of the HER2 antibody-drug conjugate trastuzumab-DM1 (T-DM1) in patients (pts) with HER2-positive metastatic breast cancer (MBC) previously treated with trastuzumab, lapatinib, and chemotherapy. Ann Oncol 2010; 21: (Suppl. 8): viii97. abstr 277.
  • 49
    Girish S, Gupta M, Wang B, Lu D, Krop IE, Vogel CL, Burris HA III, LoRusso PM, Yi J-H, Saad O, Tong B, Chu Y-W, Holden S, Joshi A. Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody-drug conjugate in development for the treatment of HER2-positive cancer. Cancer Chemother Pharmacol 2012; 69: 12291240.
  • 50
    Dijkers EC, Oude Munnink TH, Kosterink JG, Brouwers AH, Jager PL, de Jong JR, van Dongen GA, Schröder CP, Lub-de Hooge MN, de Vries EG. Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. Clin Pharmacol Ther 2010; 87: 586592.
  • 51
    Fishkin N, Maloney EK, Chari RV, Singh R. A novel pathway for maytansinoid release from thioether linked antibody-drug conjugates (ADCs) under oxidative conditions. Chem Commun (Camb) 2011; 47: 1075210754.
  • 52
    Hurvitz S, Dirix L, Kocsis J, Gianni L, Lu J, Vinholes J, Song C, Tong B, Chu YW, Perez EA. Trastuzumab emtansine (T-DM1) vs. trastuzumab plus docetaxel (H+T) in previously-untreated HER2-positive metastatic breast cancer (MBC): primary results of a randomized, multicenter, open-label Phase II study (TDM4450g/BO21976). Eur J Cancer 2011; 47: S330. abstr 5001.
  • 53
    Dang CT, Gianni L, Romieu G, Dirix L, Campone M, Citron ML, Zamagni C, Krop IE, Xu N, Smitt M, Suter T. Cardiac safety in a phase II study of trasuzumab emtansine (T-DM1) following anthracycline-based chemotherapy as adjuvant or neoadjuvant therapy for early-stage HER2-positive breast cancer. J Clin Oncol 2012; 30: (Suppl.): abstr 532.
  • 54
    Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, Pegram MD, Oh D-Y, Dieras V, Guardino E, Fang L, Lu MW, Olsen SR, Blackwell K. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 2012; 367: 17831791.
  • 55
    Yamashita-Kashima Y, Shu S, Harada N, Fujimoto-Ouchi K. Potentiation of trastuzumab emtansine (T-DM1)-driven antitumor activity by pertuzumab in a HER2-positive gastric cancer model. J Clin Oncol 2012; 30: (Suppl.): abstr e13502.
  • 56
    Hurvitz SA, Kakkar R. The potential for trastuzumab emtansine in human epidermal growth factor receptor 2 positive metastatic breast cancer: latest evidence and ongoing studies. Ther Adv Med Oncol 2012; 4: 235245.
  • 57
    Tse KF, Jeffers M, Pollack VA, McCabe DA, Shadish ML, Khramtsov NV, Hackett CS, Shenoy SG, Kuang B, Boldog FL, MacDougall JR, Rastelli L, Herrmann J, Gallo M, Gazit-Bornstein G, Senter PD, Meyer DL, Lichenstein HS, LaRochelle WJ. CR011, a fully human monoclonal antibody-auristatin E conjugate, for the treatment of melanoma. Clin Cancer Res 2006; 12: 13731382.
  • 58
    Rose AAN, Grosset A-A, Dong Z, Russo C, MacDonald PA, Bertos NR, St-Pierre Y, Simantov R, Hallett M, Park M, Gaboury L, Siegel PM. Glycoprotein Nonmetastatic B is an independent prognostic indicator of recurrence and a novel therapeutic target in breast cancer. Clin Cancer Res 2010; 16: 21472156.
  • 59
    Hamid O, Sznol M, Pavlick AC, Kluger HM, Kim KB, Boasberg PD, Simantov R, Davis TA, Crowley E, Hawthorne T, Green J, Hwu P. Frequent dosing and GPNMB expression with CDX-011 (CR011-vcMMAE), an antibody-drug conjugate (ADC), in patients with advanced melanoma. J Clin Oncol 2010; 28: (Suppl.): abstr 8525.
  • 60
    Saleh M, Bendell J, Rose A, Siegel PM, Hart L, Sirpal S, Jones S, Crowley E, Simantov R, Vahdat L. Correlation of GPNMB expression with outcome in breast cancer (BC) patients treated with the antibody-drug conjugate (ADC), CDX-011 (CR011-vcMMAE). J Clin Oncol 2010; 28: (Suppl.): abstr 1095.
  • 61
    Griffin JD, Hercend T, Beveridge R, Schlossman SF. Characterization of an antigen expressed by human natural killer cells. J Immunol 1983; 130: 29472951.
  • 62
    Roguska MA, Pedersen JT, Henry AH, Searle SMJ, Roja CM, Avery B, Hoffee M, Cook S, Lambert JM, Blättler WA, Rees AR, Guild BC. A comparison of two murine monoclonal antibodies humanized by CDR-grafting and variable domain resurfacing. Protein Eng 1996; 9: 895904. (Erratum: Protein Eng 1997; 10: 181).
  • 63
    Lanier LL, Chang C, Azuma M, Ruitenberg JJ, Hemperly JJ, Phillips JH. Molecular and functional analysis of human natural killer cell-associated neural cell adhesion molecule (N-CAM/CD56). J Immunol 1991; 146: 44214426.
  • 64
    Tassone P, Gozzini A, Goldmacher V, Shammas MA, Whiteman KR, Carrasco DR, Li C, Allam CK, Venuta S, Anderson KC, Munshi NC. In vitro and in vivo activity of the maytansinoid immunoconjugate huN901-N2′-deacetyl-N2′-(3-mercapto-1-oxopropyl)-maytansine against CD56+ multiple myeloma cells. Cancer Res 2004; 64: 46294636.
  • 65
    Jensen M, Berthold F. Targeting the neural cell adhesion molecule in cancer. Cancer Lett 2007; 258: 921.
  • 66
    Roy DC, Ouellet S, Le Houillier C, Ariniello PD, Perreault C, Lambert JM. Elimination of neuroblastoma and small cell lung cancer cells with an anti-neural cell adhesion molecule immunotoxin. J Natl Cancer Inst 1996; 88: 11361145.
  • 67
    Whiteman KR, Murphy MF, Cohane KP, Sun W, Carrigan CN, Mayo MF, Li Y, Lutz RJ. Preclinical evaluation of IMGN901 (huN901-DM1) as a potential therapeutic for ovarian cancer. Proc Am Assoc Cancer Res 2008; 49: abstr 2135.
  • 68
    Chari RVJ, Xie H, Steeves RM, Lambert JM. Additive and synergistic effects of combination treatment with huN901-DM1 (BB-10901) and chemotherapeutic agents in small cell lung cancer xenograft tumor models. Proceedings of AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics. 2005; 70, abstr A58.
  • 69
    Woll P, Fossella FV, O'Brien MO, Clinch Y, Donaldson K, O'Keeffe J, Zildjian S, Fram R, Qin A, Lorigan P. Phase I study of IMGN901 (BB-10901) in patients with CD56-positive solid tumors. Eur J Cancer 2008; 6: (Suppl.): abstr 510.
  • 70
    Woll PJ, O'Brien M, Fossella F, Shah M, Clinch Y, O'Keeffe J, Qin A, O'Leary J, Lorigan P. Phase I study of lorvotuzumab mertansine (IMGN901) in patients with CD56-positive solid tumors. Ann Oncol 2010; 21: (Suppl. 8): abstr 536P.
  • 71
    Chanan-Khan A, Wolf J, Garcia J, Gharibo M, Jagannath S, Manfredi D, Sher T, Martin C, Zildjian SH, O'Leary J, Vescio R. Efficacy analysis from a phase I study of lorvotuzumab mertansine (IMGN901) used as monotherapy in patients with heavily pre-treated CD56-positive multiple myeloma. Blood 2010; 116: 819. Abstr 1962.
  • 72
    Tolcher AW, Forouzesh B, McCreery H, Hammond L, Patnaik A, Lambert J, Xie H, Hoffee M, Zentgraf R, Zinner R, Glisson B, Clinch Y, Barrington P, Rowinsky E, Fossella F. A phase I and pharmacokinetic study of BB-10901, a maytansinoid immunoconjugate, in CD56 expressing tumors. Eur J Cancer 2002; 38: (Suppl. 7): S152153. Abstr 509.
  • 73
    McCann J, Fossella FV, Villalona-Calero MA, Tolcher AW, Fidias P, Raju R, Zildjian S, Giuld R, Fram R. Phase II trial of huN901-DM1 in patients with relapsed small cell lung cancer (SCLC) and CD56-positive small cell carcinoma. J Clin Oncol 2007; 25: (18S): Abstr 18084.
  • 74
    Fossella F, Woll PJ, Lorigan P, Tolcher A, O'Brien M, O'Keeffe J, Zildjian S, Qin A, O'Leary J, Villalona-Calero M. Clinical experience of IMGN901 (BB-10901) in patients with small cell lung carcinoma. J Thorac Oncol [13th World Conference on Lung Cancer, 2009] 2009; 4(Suppl. 9), Abstr 6327. (PD4.3.5).
  • 75
    Berdeja JG, Ailawadhi S, Weitman SD, Zildjian S, O'Leary JJ, O'Keeffe J, Guild R, Whiteman K, Sher T, Chanan-Khan A. Phase I study of lorvotuzumab mertansine (LM, IMGN901) in combination with lenalidomide (Len) and dexamethasone (Dex) in patients with CD56-positive relapsed or relapsed/refractory multiple myeloma (MM). J Clin Oncol 2011; 29: (Suppl.): abstr 8013.
  • 76
    Allen PJ, Bowne WB, Jaques DP, Brennan MF, Busam K, Coit DG. Merkel cell carcinoma: prognosis and treatment of patients from a single institution. J Clin Oncol 2005; 23: 23002309.
  • 77
    Carrigan CN, Xu S, Zhao Y, Testa N, Gabriel R, O'Keefe J, Qin A, O'Leary J, Payne G, Lutz RJ. The antigen target of lorvotuzumab mertansine (IMGN901), CD56, is expressed at significant levels in Merkel cell carcinoma (MCC). Proc Am Assoc Cancer Res 2010; 51: abstr 5335.
  • 78
    Whiteman KR, Ab O, Bartle LM, Foley K, Goldmacher VS, Lutz RJ. Efficacy of IMGN901 (huN901-DM1) in combination with bortezomib and lenalidomide against multiple myeloma cells in preclinical studies. Proc Am Assoc Cancer Res 2008; 49: abstr 2146.
  • 79
    Whiteman KR, Johnson HA, Xu S, Pinkas J, Lutz RJ. Lorvotuzumab mertansine (IMGN901) in combination with standard-of-care paclitaxel/carboplatin therapy is highly active in a preclinical xenograft model of ovarian cancer. Proc Am Assoc Cancer Res 2011; 52: abstr 1781.
  • 80
    Whiteman KR, Johnson H, Xu S, Moreland J, Vyas V, Bartle LM, Ab O, Carrigan C, Pinkas J, Lutz RJ. Combination therapy with IMGN901 and lenalidomide plus low-dose dexamethasone is highly effective in multiple myeloma xenograft models. Proc Am Assoc Cancer Res 2009; 50: abstr 2799.
  • 81
    Berdeja JG, Ailawadhi MD, Niesvizky R, Wolf JL, Zildjian SH, O'Leary J, Chanan-Khan A. Phase I study of lorvotuzumab mertansine (IMGN901) in combination with lenalidomide and dexamethasone in patients with CD56-positive relapsed or relapsed/refractory multiple myeloma – a preliminary safety and efficacy analysis of the combination. Blood 2010; 116: abstr 1934.
  • 82
    Spigel DR, Bendell J, Mita AC, Argiris A, Kurkjian C, Hann CL, Segota Z, Guild R, Mastico R, Gutierrez ME. Phase I/II study to assess the safety, pharmacokinetics (PK) and efficacy of lorvotuzumab mertansine (LM, IMGN901) in combination with carboplatin/etoposide in patients with solid tumors including small-cell lung cancer (SCLC). 37th ESMO Congress, Vienna. Ann Oncol 2012; 23: (Suppl. 9): Abstr 1543TiP.
  • 83
    Nadler LM, Anderson KC, Marti G, Bates M, Park E, Daley JF, Schlossman SF. B4, a human B lymphocyte-associated antigen expressed on normal, mitogen activated, and malignant B lymphocytes. J Immunol 1983; 131: 244250.
  • 84
    Roguska MA, Pedersen JT, Keddy CA, Henry AH, Searle SJ, Lambert JM, Goldmacher VS, Blättler WA, Rees AR, Guild BC. Humanization of murine monoclonal antibodies through variable domain resurfacing. Proc Natl Acad Sci USA 1994; 91: 969973.
  • 85
    Blanc V, Bousseau A, Caron A, Carrez C, Lutz RJ, Lambert JM. SAR3419: an anti-CD19-maytansinoid immunoconjugate for the treatment of B-cell malignancies. Clin Cancer Res 2011; 17: 64486458.
  • 86
    Lutz RJ, Zuany-Amorim C, Vrignaud P, Mayo MF, Guerif S, Xie H, Blanc V, Bissery MC, Hercend T. Preclinical evaluation of SAR3419 (huB4-DM4), an anti-CD19-maytansinoid immunoconjugate, for the treatment of B-cell lymphoma. Proc Am Assoc Cancer Res 2006; 47: abstr 3731.
  • 87
    Al Katib AM, Aboukameel A, Mohammad R, Bissery M-C, Zuany-Amorim C. Superior antitumor activity of SAR3419 to rituximab in xenograft models for non-Hodgkin's lymphoma. Clin Cancer Res 2009; 15: 40384045.
  • 88
    Younes A, Gordon L, Kim S, Romaguera J, Copeland AR, de Castro Farial S, Kwak L, Fayad L, Hagemeister F, Fanale M, Lambert J, Bagulho T, Morariu-Zamfir R. Phase I multi-dose escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous (IV) infusion every 3 weeks to patients with relapsed/refractory B-cell non-Hodgkin's lymphoma (NHL). Blood 2009; 114: abstr 585.
  • 89
    Younes A, Kim S, Romaguera J, Copeland A, Farial SD, Kwak LW, Fayad L, Hagemeister F, Fanale M, Neelapu S, Lambert JM, Morariu-Zamfir R, Payrard S, Gordon LI. Phase I multidose-escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous infusion every 3 weeks to patients with relapsed/refractory B-cell lymphoma. J Clin Oncol 2012; 30: 27762782.
  • 90
    Coiffier B, Ribrag V, Dupuis J, Tilly H, Haioun C, Morschhauser F, Lamy T, Brehar O, Houot R, Lambert J, Morariu-Zamfir R. Phase I/II study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered weekly to patients (pts) with relapsed/refractory B-cell non-Hodgkin lymphoma (NHL). J Clin Oncol 2011; 29: abstr 8017.
  • 91
    Coiffier B, Morschhauser F, Dupuis J, Haioun C, Laine F, Houot R, Tilly H, Brehar O, Lambert J, Fagniez N, Payrard S, Ribrag V. Phase I study cohort evaluating an optimized administration schedule of SAR3419, an anti-CD19 DM4-loaded antibody-drug conjugate (ADC), in patients (pts) with CD19 positive relapsed/refractory B-cell non-Hodgkin's lymphoma (NCT00796731). J Clin Oncol 2012; 30: abstr 8057.
  • 92
    Oflazoglu E, Stone IJ, Gordon K, Wood CG, Repasky EA, Grewal IS, Law CL, Gerber HP. Potent anticarcinoma activity of the humanized anti-CD70 antibody h1F6 conjugated to the tubulin inhibitor auristatin via an uncleavable linker. Clin Caner Res 2008; 14: 61716180.
  • 93
    Thompson JA, Forero-Torres A, Heath EI, Ansell SM, Pal SK, Infante JR, de Vos S, Hamlin PA, Zhao B, Klussman K, Whiting NC. SGN75: the effect of SGN-75, a novel antibody–drug conjugate (ADC), in treatment of patients with renal cell carcinoma (RCC) or non-Hodgkin lymphoma (NHL): a phase I study. J Clin Oncol 2011; 29: (Suppl.): abstr 3071.
  • 94
    Wang X, Ma D, Olson WC, Heston WD. In vitro and in vivo responses of advanced prostate tumors to PSMA ADC, an auristatin-conjugated antibody to prostate-specific membrane antigen. Mol Cancer Ther 2011; 10: 17281739.
  • 95
    Mega AE, Petrylak DP, Kantoff P, Stephenson J, Vogelzang NJ, Dreicer R, Shore ND, Stambler N, Carpenito J, D'Ambrosio P, Israel RJ. Prostate-specific membrane antigen antibody drug conjugate (PSMA ADC): a phase I trial in metastatic castration-resistant prostate cancer (mCPRC) previously treated with a taxane. J Clin Oncol 2012; 30: (Suppl.): abstr 4662.
  • 96
    Gudas JM, Torgo M, An Z, Jia XC, Morrison KJ, Morrison RK, Kanner SB, Raitano AB, Jakobovits A. AGS-16M8F: a novel antibody-drug conjugate (ADC) for treating renal and lier cancers. ASCO Genitourinary Cancers Symposium 2010. abstr 328.
  • 97
    Morris MJ, Bruce JY, Reyno LM, Anand B, Hartford A, Jelaca-Maxwell K, Lackey J, Eisenberger MA. Phase I trial of ASG-5ME in metastatic castration-resistant prostate cancer (CRPC). J Clin Oncol 2012; 30: (Suppl.): abstr 4568.
  • 98
    Tassone P, Goldmacher VS, Neri P, Gozzini A, Shammas MA, Whiteman KR, Hylander-Gans LL, Carrasco DR, Hideshima T, Shringarpure R, Shi J, Allam CK, Wijdenes J, Venuta S, Munshi NC, Anderson KC. Cytotoxic activity of the maytansinoid immunoconjugate B-B4-DM1 against CD138+ multiple myeloma cells. Blood 2004; 104: 36883696.
  • 99
    Ikeda H, Hideshima T, Fulciniti M, Lutz RJ, Yasui H, Okawa Y, Lutz RJ, Yasui H, Okawa Y, Kiziltepe T, Vallet S, Pozzi S, Santo L, Perrone G, Tai YT, Cirstea D, Raje NS, Uherek C, Dälken B, Aigner S, Osterroth F, Munshi N, Richardson P, Anderson KC. The monoclonal antibody nBT062 conjugated to cytotoxic maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo. Clin Cancer Res 2009; 15: 40284037.
  • 100
    Jagannath S, Chanan-Khan A, Heffner LT, Avigan D, Zimmerman TM, Lonial S, Lutz RJ, Engling A, Uherek C, Osterroth F, Ruehle M, Beelitz MA, Niemann G, Wartenberg-Demand A, Haeder T, Anderson KA, Munshi N. BT062, an antibody-drug conjugate directed against CD138, shows clinical activity in patients with relapsed or relapsed/refractory multiple myeloma. Blood 2011; 118: abstr 305.
  • 101
    Beck A, Lambert J, Sun M, Lin K. Fourth world antibody-drug conjugate summit. MAbs 2012; 4: 637647.
  • 102
    Carrigan C, Zuany-Amorim C, Mayo M, Tavares DJ, Lutz RJ, Kellogg EA, Blanc V, Vrignaud P, Bissery M, Payne G. Preclinical evaluation of SAR566658 (huDS6-DM4) in mice bearing human tumor xenografts of breast, ovarian, lung, cervical and pancreatic cancer. Eur J Cancer 2008; 6: 166. abstr 525.
  • 103
    Schatz CA, Golfier S, Scheider C, Kopitz C, Berhorster K, Henderson D, Schmitz A, Krahn T, Kreft B. Efficacy and candidate biomarker evaluation for the anti-mesothelin antibody drug conjugate (ADC) BAY 94-9343, mesothelin-ADC in mesothelin-positive preclinical xenograft models. Proc Am Assoc Cancer Res 2012; 72: (8 Suppl.): abstr 2726.
  • 104
    Park PU, Yi Y, Li M, Chicklas S, Lai KC, Mayo MF, Coccia JA, Deckert J, Pinkas J, Chittenden TD. Antibody and linker selection for the anti-CD37 antibody-maytansinoid conjugate IMGN529 for the treatment of B-cell malignancies. Proc Am Assoc Cancer Res 2011; 71: abstr 2830.
  • 105
    Deckert J, Mayo MF, Yi Y, Li M, Chicklas S, Tavares DJ, Pinkas J, Chittenden TD, Lutz RJ, Lambert JM, Park P. IMGN529: a therapeutic maytansinoid conjugate of an anti-CD37 antibody with multiple mechanisms of action for B-cell lymphoma and leukemia. Proc Am Assoc Cancer Res 2011; 71: abstr 4565.
  • 106
    Ab O, Bartle LM, Rui L, Coccia J, Johnson HA, Whiteman KR, Kellogg B, Clancy L, Sun X, Goldmacher VS. IMGN853, an anti-folate receptor I antibody-maytansinoid conjugate for targeted cancer therapy. Proc Am Assoc Cancer Res 2011; 71: abstr 4576.
  • 107
    Whiteman KR, Johnson HA, Xu S, Carrigan CN, Ab O, Pinkas J. Preclinical evaluation of IMGN853, an anti-FOLR1 antibody-maytansinoid conjugate, as a potential therapeutic for ovarian cancer. Proc Am Assoc Cancer Res 2011; 71: abstr 1760.
  • 108
    Thon JN, Devine MT, Jurak Begonja A, Tibbitts J, Italiano JE Jr. High-content live-cell imaging assay used to establish mechanism of trastuzumab emtansine (T-DM1)-mediated inhibition of platelet production. Blood 2012; 120: 19751984.
  • 109
    Bender BC, Schaedeli-Stark F, Kock R, Joshi A, Chu YW, Rugo H, Krop IE, Girish S, Friberg LE, Gupta M. A population pharmacokinetic/pharmacodynamic model of thrombocytopenia characterizing the effect of trastuzumab emtansine (T-DM1) on platelet counts in patients with HER2-positive metastatic breast cancer. Cancer Chemother Pharmacol 2012; 70: 591601.